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Abstract: 
Colorectal cancer (CRC) biopsies underpin accurate diagnosis, but are also relevant 
for patient stratification in molecularly-guided clinical trials. The consensus molecular 
subtypes (CMS) and colorectal cancer intrinsic subtypes (CRIS) transcriptional 
signatures have potential clinical utility for improving prognostic/predictive patient 
assignment. However, their ability to provide robust classification, particularly in pre-
treatment biopsies from multiple regions or at different time points remains untested.  
In this study, we undertook a comprehensive assessment of the robustness of CRC 
transcriptional signatures, including CRIS and CMS, using a range of tumour 
sampling methodologies currently employed in clinical and translational research. 
These include analyses using (i) laser-capture microdissected CRC tissue, (ii) eight 
publically available rectal cancer biopsy data sets (n=543), (iii) serial biopsies (from 
AXEBeam trial, NCT00828672; n=10), (iv) multi-regional biopsies from colon 
tumours (n=29 biopsies, n=7 tumours) and (v) pre-treatment biopsies from the phase 
II rectal cancer trial COPERNCIUS (NCT01263171; n=44). Compared to previous 
results obtained using CRC resection material, we demonstrate that CMS 
classification in biopsy tissue is significantly less capable of reliably classifying 
patient subtype (43% unknown in biopsy versus 13% unknown in resections, 
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p=0.0001). In contrast, there was no significant difference in classification rate 
between biopsies and resections when using the CRIS classifier. Additionally, we 
demonstrated that CRIS provides significantly better spatially- and temporally- robust 
classification of molecular subtypes in CRC primary tumour tissue compared to CMS 
(p= 0.003 and p=0.02, respectively).  
These findings have potential to inform ongoing biopsy-based patient stratification in 
CRC, enabling robust and stable assignment of patients into clinically-informative 
arms of prospective multi-arm, multi-stage clinical trials.  
Keywords: Colorectal cancer; gene expression profiling; molecular stratification; 
biopsy; transcriptional signatures; intrinsic subtypes; consensus molecular subtypes 
 
Introduction: 
Recent studies have defined the molecular taxonomy of colorectal cancer (CRC) by 
transcriptional, methylation and mutational profiling [1-5], culminating in publication 
of four consensus molecular subtypes (CMSs) [6], two of which reflect pathological 
well-defined entities within the tumour microenvironment(TME): CMS1(high immune-
cell infiltration; better prognosis), CMS4 (high relative density of stroma, particularly 
fibroblasts; poorer prognosis) [7]. A second classification, the CRC intrinsic subtypes 
(CRIS), utilises epithelial-specific gene expression to potentially provide 
prognostic/predictive value [8,9].  
Using macrodissected tissue from central tumour (CT), invasive front (IF) and lymph 
node (LN) from individual patients (patients n=24; samples n=72), we previously 
demonstrated the potential for discordant assignment of these patient-of-origin 
matched samples when using transcriptional classifiers, as different CMS 
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classifications were mapped to different regions of the same tumour, due to stromal-
derived intratumoural heterogeneity (ITH) [10]. We further demonstrated that this 
confounding effect could be resolved by using epithelial-rich or cancer-cell intrinsic 
subtypes, such as CRIS, which demonstrated superior “spatial concordance”, with 
identical CRIS classification achieved across multiple regions-of-origin in patient-
matched samples [11].  
The potential clinical utility of both CMS and CRIS molecular subtyping has been 
extensively validated in CRC resection specimens, and while molecular profiling of 
surgical resection material is possible in large retrospective studies [1], the suitability 
of CRC biopsy material for prospective molecular stratification has not been 
comprehensively assessed. This is increasingly important, given the number of 
molecularly-guided CRC trials that require profiling of pre-treatment biopsies for 
patient stratification [12]. 
In this current study, we assessed the spatial and temporal stability of clinically-
relevant molecular signatures in diagnostic biopsy material in three potentially 
clinically relevant scenarios. We utilised a multi-regional (CT and IF) laser capture 
microdissected (LCM) CRC cohort to examine if stromal-ITH occurs with this more 
precise specimen-preparation methodology. Additionally, we assessed subtyping 
robustness in a meta-analysis of publicly available rectal cancer biopsy datasets. We 
also performed temporal/spatial assessment of the stability of these classifiers, using 
both patient-matched serial biopsies collected over a three week period from the 
phase II AXEBeam study [13] and multi-region-of-origin colon biopsies from the 
Biopsies of Surgical Specimens (BOSS) study [14]. Finally, as part of 
S:CORT(Stratification in COloRecTal cancer) research programme [12,15], we 
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assessed the ability of CRIS and CMS to classify histologically-diverse rectal biopsy 
samples from the phase II COPERNICUS study.  
 
 
Materials and methods: 
Study design 
The study design is summarised in supplementary material, Figure S1 with details of 
patient cohorts outlined below. Initially, we assessed the patient-clustering 
capabilities of CRC gene signatures in a LCM cohort of invasive front (IF) and central 
tumour (CT) regions. We assessed proportions of CRIS and CMS molecular 
subtypes [6,8] in biopsy material from publically available rectal cancer biopsy gene 
expression datasets (in GEO); details of these cohorts are outlined in Table 1. We 
assessed the temporal and spatial stability of CRIS and CMS signatures in biopsy 
samples from AXEBeam and BOSS studies respectively [13,14]. Finally, we 
performed molecular analysis of biopsies from the COPERNICUS study. 
Publically available data sets 
All public datasets were downloaded from gene expression omnibus (GEO) 
(https://www.ncbi.nlm.nih.gov/geo/). Rectal cancer biopsy datasets are detailed in 
Table 1. All datasets with sufficient probe-to-gene annotations and sample size 
(n>20) were curated. When possible, raw unprocessed data were downloaded and 
expression profiles underwent standard Robust Multi-array Average (RMA) 
normalisation prior to molecular subtyping. When only post-processed data was 
available, we downloaded series matrices to perform molecular subtyping. All probes 
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were used and no variance filtering was performed on any data prior to molecular 
subtyping, to ensure presence of all 273 CMS genes and 565 CRIS genes from the 
published classification models.  
LCM CRC cohort 
GSE65480 is composed of LCM CRC tissue from 20 matched IF and CT regions, 
profiled using the Affymetrix Human Gene 1.0 ST Array.  
Colon and rectal cancer biopsy datasets 
Full details for arrays employed and sample numbers analysed  for each cohort are 
detailed in Table 1, with GEO accession numbers and brief clinical details for the 
rectal cancer meta-dataset summarised below. GSE56699 consists of 58 pre-
treatment rectal cancer formalin-fixed paraffin-embedded (FFPE) biopsy specimens 
from patients treated with preoperative radiotherapy. GSE94104 consists of 48 
locally advanced rectal cancer (LARC) pre-treatment biopsy specimens from patients 
treated with long course preoperative 5-FU based chemoradiotherapy. GSE3493 
contains 46 pre-treatment rectal cancer biopsies from patients treated with 
preoperative radiation.  GSE68204 comprises 38 pre-treatment LARC biopsies 
specimens from patients treated with preoperative chemoradiotherapy. GSE35452 
consists of 46 pre-treatment rectal cancer biopsies from patients treated with 5-
fluorouracil- and irinotecan-based preoperative chemoradiotherapy. GSE46862 
contains 69 rectal cancer pre-treatment biopsies from patients treated with 
preoperative chemoradiotherapy. GSE45404 consists of 42 pre-treatment rectal 
cancer biopsies from patients treated with preoperative 5-fluorouracil and oxaliplatin-
based preoperative chemoradiotherapy. We utilised 196 pre-treatment rectal cancer 
biopsies from GSE87211 where patients were treated with a preoperative 
chemoradiotherapy regimen consisting of 5-FU alone and FOLFOX.  
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Colon cancer multi-region-of-origin biopsy cohort 
To assess the spatial stability of CMS and CRIS in biopsy samples, we utilised 
transcriptional profiles from the BOSS study, which were downloaded from 
GSE85043. This dataset consists of 29 multiregional biopsies from seven patients. 
Samples were profiled using the Affymetrix Human Genome U133 Plus 2.0 Array. 
Importantly, each biopsy had been randomly taken from the surgical specimen using 
endoscopic biopsy forceps to simulate the clinical environment.  
Longitudinal serial rectal biopsy cohort  
Material from 10 matched biopsy samples from patients recruited to the AXEBeam 
phase II trial (NCT00828672; GSE60331) was profiled using the Affymetrix 
Primeview array. This trial investigated the efficacy of bevacizumab/chemo-radiation 
combination in rectal cancer. Biopsies were taken before therapy and three weeks 
into the first cycle of bevacizumab, but before chemo-radiation. 
Clinical trial cohort 
COPERNICUS is a phase 2 study of neoadjuvant oxaliplatin-based chemotherapy, 
followed by short course radiotherapy and surgical resection in patients with rectal 
cancer. Within S:CORT, we generated transcriptional profiles using the Affymetrix 
Almac Xcel array from the COPERNICUS (NCT01263171) trial cohort (52 biopsy 
samples); 50 samples (96.2%) generated suitable quantities of RNA for analysis, 
while 44 (84.6%) yielded robust transcriptional profiles. 
Gene signatures 
We previously evaluated eight CRC gene expression signatures for variation in their 
ability to robustly cluster matched multi-region-of-origin CRC gene expression 
profiles [11]. To validate the novel results generated in the current study using an 
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independent dataset, we employed the same eight gene expression signatures as 
previously published [11]. The 30 gene signature was developed as a classifier of 
“region-of-origin” from a cohort of 24 patient samples using patient-matched samples 
from IF, CT and LN regions (total n=24). This cohort is available from the NCBIGEO 
repository under accession number GSE95109.[10] The Jorissen et al signature [16] 
was developed using transcriptional profiles from 553 colorectal samples using 
Affymetrix HG-U133Plus2.0 GeneChip arrays, to develop a 163 gene “metastasis 
classifier”, which could stratify stage B and C samples into prognostic subtypes. The 
Eschrich et al signature [17] was developed using cDNA array profiles from 78 colon 
tumours samples to generate a 43 gene prognostic signature. The Sadanandam et 
al signature [5] (a surrogate for CMS) was developed using transcriptional profiles 
from 445 primary CRC resections using Affymetrix HG-U133Plus2.0 GeneChip 
arrays to define 786 subtype-specific signature genes. The 207 genes associated 
with classification of the “stem-like” subtype from the original Sadanandam et al 
signature were used as our stem-like (CMS4) signature. The Kennedy et al signature 
[18] used stage II FFPE colon cancer tumours on the Almac Colorectal Cancer DSA 
platform to define a 634 probeset stage II prognostic signature. The Popovici et al 
signature[19] was developed using 668 stage II/III FFPE colon cancer tissue 
samples from the PETACC-3 phase III clinical trial on the Almac Colorectal Cancer 
DSA platform. A 64 gene classifier was developed, which identifies samples with 
signalling similar to BRAF-mutant tumours. The colorectal intrinsic signature (CRIS) 
[9] was developed using transcriptional profiles from 515 patient-derived xenograft 
tumours using Illumina human-specific 48k gene chips. A 565-gene classifier was 
developed, which identified five subtypes based on their intrinsic epithelial 
expression profile. 
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We previously indicated that the 30 gene, stem-like (CMS4), Jorissen and Eschrich 
gene signatures contain genes highly expressed in fibroblasts, the Sadanandam 
(CMS) and Kennedy signatures have a more balanced expression across cell types, 
whilst the Popovici and CRIS gene signatures contain predominantly epithelial-
specific gene signatures [11].   
In addition to the previous eight gene expression signatures, we assessed the 
clustering capabilities of a recently published refined CMS protein expression 
classifier [20], which consists of four proteins – CDX2, FRMD6, HTR2B and ZEB1, 
developed using tissue microarray analysis in combination with MSI genotyping, to 
classify CMS1 (based solely on MSI) and a combined CMS2/3 and CMS4 subtypes. 
In this publication, CDX2 is used a marker for epithelial-like tumours (CMS2/3) 
whereas FRMD6, ZEB1 and HTR2B have higher expression in mesenchymal-like 
tumours (CMS4).  
Patient classification 
To validate the improved ability of CRIS gene signatures to classify by patient-of-
origin rather than region-of-origin, we utilised divisive analysis clustering (DIANA) 
and normalised Pearson similarity scoring. This Pearson score was used to define 
the ratio between the covariance and the standard deviation of the multi-region CRC 
samples, where higher ratios (up to 1) indicate increased similarity. These two 
methodologies, as previously published, assess variation in clustering between gene 
signatures [11]. CMS and CRIS subtypes were assigned to each gene expression 
profile using the previously published methods [6,8,11]. This combined approach of 
utilising the published molecular subtyping CMS and CRIS classifiers, alongside two 
independent patient clustering methods (Pearson similarity score and DIANA) will 
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reduce the possibility that our findings are confounded by a methodology bias 
specific to any particular classification algorithm. 
 
Statistical Analysis and Graphical Representation 
Other statistical analyses, including Fisher’s exact and unpaired t-tests, were 
performed using GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA) . Plots 
for integrative visualisation purposes were generated using StratomeX tool within 
Caleydo software version 3.1.5 downloaded from 
(http://caleydo.org/tools/stratomex/).  
Assessing tumour content in COPERNICUS samples 
A visual assessment of neoplastic cell content, performed only within the 
macrodissected area of tissue used for molecular profiling, was made at 4x 
magnification. This value was estimated by a pathologist blinded to CMS and 
molecular data. 
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Results  
Patient stratification in epithelial-enriched LCM CRC specimens 
Samples from a cohort of CRC tumour resection tissue samples that had been 
dissected into CT and IF regions using LCM were evaluated using a series of 
transcriptional profiling approaches (see Materials and Methods). Importantly, as this 
dataset has been generated using LCM epithelial tissue, it more closely resembles 
an epithelial-enriched CRC biopsy sample, rather than the macrodissected resection 
tissue used in our previous studies [10,11].  
First, we employed the published CMS classifier (which uses a random forest (RF) 
posterior probability score) to evaluate each matched CT and IF sample. Using this 
method, each tissue sample is assigned a score for each individual CMS class (i.e. a 
sample will have a score for CMS1, CMS2, CMS3 and CMS4), before a final 
classification is made. Using these individual CMS scores, we created a CMS ratio 
based on the change in RF score, from CT and IF regions, for each patient-matched 
sample (Figure 1A).  We demonstrated an increase in relative classification score for 
CMS1 and 4 subtypes (the stromal subtypes) in IF samples compared to patient-
matched CT samples in this LCM cohort.  In contrast, the ratios for CMS2 and 3 (the 
epithelial subtypes) showed a decrease in the IF regions compared to the CT 
regions (Figure 1A; left, GSE65480, n=20 and supplementary material, Figure S2A). 
When comparing the normalised random forest classification scores between 
combined stromal (CMS1, 4) and epithelial subtypes (CMS2, 3) we observed a 
statistically significant difference between the two groups (Figure 1A, right, Student’s 
t-test, p=0.0001 and supplementary material, Figure S2B).  
We next used a Pearson similarity score in conjunction with eight CRC-specific 
classifiers (see Materials and Methods and [11]) to assess robustness of 
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classification in these patient-matched samples. This Pearson similarity analysis 
indicates variation in transcriptional classification of patient matched samples (higher 
ratios indicate increased similarity), allowing a focus on the biology underlying the 
classification system. Using this method, we highlighted high levels of concordance 
of patient-matched samples from different regions of the tumour when using gene 
signatures that focused on cancer cell intrinsic signalling (CRIS, Popovici) compared 
to stromal dependent signatures (Figure 1B). Divisive clustering, using the DIANA 
methodology, also demonstrated that these signatures correctly clustered patient-
matched samples from different tumour regions, (CRIS 95%, Popovici 85%) 
compared to stromal-derived signatures (Figure 1C, supplementary material, Figure 
S3). Furthermore, we attempted to use our transcriptional data in combination with a 
refined CMS classifier [20], with the caveat that this refined classifier was originally 
developed using four protein expression immunohistochemistry (IHC) markers to 
distinguish CMS2/3 from CMS4. Using this refined IHC CMS classifier, we again 
observe poor patient-matching correlation of our transcriptional data using DIANA 
(supplementary material, Figure S4).  
Additionally, when re-employing the CMS RF classifier, alongside the Nearest 
template predictor (NTP) CRIS classification method, we observed increased 
concordance in spatial stability (correct identification of Patient-of-Origin) in multi-
regional samples when employing CRIS as compared to CMS classification (Figure 
1D; CRIS concordance 60% versus CMS 15%, p=0.003, Fisher’s exact). We 
observed that 40% of all LCM cohort samples profiled cannot be confidently 
assigned to a CMS group (termed UNK), particularly in IF samples; only 5% CRIS-
UNKs are observed in the same sample series (Figure 1D; p=0.0001, Fisher’s 
exact).  
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Molecular subtype assessment in CRC biopsy meta-dataset  
We utilised the online repository GEO by searching for “rectal cancer” datasets (to 
1st March 2017) to curate a meta-dataset containing 543 treatment-naïve rectal 
cancer biopsy gene expression profiles from eight independent datasets (full details 
in Materials and Methods and Table 1). This meta-dataset consists of gene 
expression profiles from five different gene expression platforms, enabling both 
comparative assessment between molecular subtyping techniques and cross-
platform correlation (Table 1).  
We classified each individual dataset using the CMS method [6], resulting in 
assignment of an UNK classification in 43% (n=252) of patient samples (Figure 2A 
and B; range 24-70%). This finding, specifically in biopsy samples, is considerably 
higher than the 13% previously observed in CRC resections by Guinney et al 
(p=0.0001, Fisher’s exact) [6]. In contrast, CRIS classification in the same datasets 
revealed that only 7% (n=37) of patients were UNK (Figure 2A and B; range 2-16%). 
This observed proportion of CRIS-UNKs across these biopsy datasets correlates 
with the 9.2% CRIS-UNKs identified by Isella et al [8] in CRC resection specimens 
(342 UNK from total of 3738 samples) (no significant difference, p=0.07, Fisher’s 
exact).  Direct comparison of CMS and CRIS classifications for each of the 543 
rectal cancer biopsies revealed that 94% of CMS-UNK patients could subsequently 
be assigned a CRIS subclass (Figure 1C), indicating that the transcriptomics data 
are of sufficient quality for reliable classification. These results indicated that, in 
addition to the previously identified confounding issues with stromal-derived ITH 
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when using the CMS classifier, we now demonstrate for the first time that CRIS 
provides a more robust and reproducible classification methodology for CRC patients 
when using pre-treatment biopsy samples.  
 
Temporal stability of molecular subtypes in serial biopsy samples. 
Serial biopsies can provide information on treatment response and clinically-relevant 
changes in tumour biology; therefore evaluating temporal stability of molecular 
subtypes in repeat CRC biopsies is highly relevant. We analysed transcriptional 
profiles of ten patient-matched serial biopsy samples (taken both before and 
following three weeks of bevacizumab treatment) from the AXEBeam phase II trial 
(NCT00828672; GSE60331).  Again, we confirmed a high number of UNK samples 
by CMS analysis (50%, 10/20), with only 30% (3/10) of patients displaying a 
concordant CMS classification; lack of classification  does not appear to be due to 
treatment-induced transcriptional changes, as six of the ten UNK samples were 
obtained pre-treatment. Conversely, all samples were classified by CRIS, with 90% 
(9/10) temporal concordance across matched serial biopsies taken during this 
clinical trial (Figure 3, p=0.02, Fisher’s exact).  
Spatial stability of molecular subtypes in biopsies of surgical specimens. 
We have demonstrated that the CRIS classifier provides a more spatially robust 
classification than CMS in multi-region-of-origin LCM CRC cells (Figure 1D). 
However, pre-treatment biopsies, rather than resection tissue, are increasingly being 
used for prospective molecular stratification. Therefore, we subtyped 29 
multiregional biopsies originating from 7 CRC surgical specimens (between 3–5 
multiple regions-of-origin samples per patient) from the BOSS study (GSE85043), 
using CMS and CRIS classifiers. We demonstrated that only 1/7 tumours subtyped 
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had 100% concordance in all regions biopsied using the CMS classifier, whereas 5/7 
tumours have 100% concordance using the CRIS classifier (Figure 4). Despite the 
small sample size in this cohort, these findings further confirm our observations from 
the LCM CRC cohort (Figure 1D), that CRIS shows greater spatial stability than CMS 
in clinically-relevant biopsy material. 
Patient stratification in prospective clinical trial biopsy material. 
Using transcriptional profiles from COPERNICUS (n=44) (see Materials and 
Methods), generated within S:CORT [12], we observed a higher percentage of 
patients classified as UNKs when using CMS compared to CRIS (Figure 5A; 25% 
versus 5%, p=0.013, Fisher’s exact). A detailed pathological review of H&E 
specimens was performed to test the ability of histological feature-assessment to 
predict CMS subtypes, particularly for the CMS1/CMS4 stromal-dependent subtypes. 
In a masked pathological analysis, we observed that a lower tumour and higher 
stromal percentage correlated with increased CMS1/CMS4 classification scores 
(Figure 5B, p=0.003, Student’s t-test), again emphasising the histopathological 
features underlying this classification system. This is depicted in Figure 5C by the 
representative H&E images of CMS1 (immune-enriched), CMS2/3 (epithelial-
enriched) and CMS4 (fibroblast-enriched) biopsies. 
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Discussion 
Transcriptomic dissection of CRC tumours has identified two molecular classifiers 
with potential clinical relevance. The CMS classifier identifies two histological 
subtypes; CMS1 (immune-rich), CMS4 (stromal-rich), and two epithelial-rich 
subtypes CMS2 (upregulated for WNT and MYC pathways) and CMS3 (enriched for 
KRAS mutations and activation of metabolic pathways). In contrast, the CRIS 
classifier identifies five tumour subtypes based on cancer cell intrinsic biology from 
within the TME. In this study, we assessed for the first time the ability of the CMS 
and CRIS molecular subtypes to robustly classify tumour samples, with particular 
emphasis on prospective pre-treatment biopsy tissue, when confronted with 
potential spatial and/or temporal confounders. Initially, using a cohort of patient-
matched LCM invasive front and central tumour regions from CRC resections, we 
demonstrated that the epithelial-enrichment achieved by LCM is not sufficient to 
overcome the confounding effect of stromal intratumour heterogeneity. These results 
validate our previous findings that CRIS is a more robust patient stratifier compared 
to CMS, while also indicating that epithelial-enrichment using precise but time-
consuming LCM method cannot eliminate the potential for stromal-derived ITH to 
undermine patient stratification. Our assessment of 543 rectal cancer biopsies (the 
largest rectal cancer dataset compiled to date) also revealed a significantly larger 
proportion of unclassified biopsies than has previously been reported for resection 
samples when using the CMS classifier. In contrast, the CRIS classifier assigned the 
same biopsies into proportions consistent with those observed in resection material. 
This observation indicates that while CMS classification provides important 
prognostic information in CRC resection samples, it may not be suited to 
classification in FFPE biopsy material.  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
We also demonstrated increased temporal concordance with the CRIS classifier 
when assessing longitudinal rectal cancer biopsies from patients recruited to the 
phase II AXEBeam clinical trial. As temporal stability of molecular subtypes could be 
confounded by therapy-related gene expression alteration [21] (although this is not 
indicated by our current analysis), we believe that this observation warrants further 
investigation in treatment-naïve samples or indeed with standard-of-care 
chemotherapy samples, in order to fully understand the implications of this evolving 
biology. In line with our analysis in the LCM CRC cohort and the rectal cancer meta-
dataset, we again highlighted superior spatial stability of CRIS compared to CMS in 
a multiple region-of-origin cohort using colon cancer biopsies (BOSS study). Finally, 
we coupled histopathological assessment and molecular subtyping of pre-treatment 
rectal cancer biopsies from the phase II COPERNICUS clinical trial, where we 
observed low tumour percentage (and high stromal content) to be correlated with the 
stromal CMS subtypes (CMS1 and 4).  
CRC biopsies are currently used for both cancer diagnosis and patient stratification, 
employing small panels of clinically-important biomarkers, such as RAS mutational 
status, although despite providing useful clinical information, they currently lack both 
prognostic and positive predictive value. Increasingly, biopsy samples are being 
considered for molecular stratification using high-throughput transcriptional profiling, 
particularly in the adjuvant/neo-adjuvant clinical trial setting, to aid in patient 
assignment into prognostic and/or predictive subgroups. The prognostic and 
predictive potential of CMS (and CRIS) molecular subtypes have, to date, been 
investigated using large retrospective collections of resected CRC tissue [6,8]; our 
present study highlights the need for rigorous testing and refinement of CRC 
classifiers using prospective biopsy tissue, thus facilitating their employment as 
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clinically-useful tools in patient stratification. Molecular analysis of Patient 6 from the 
BOSS study (see Figure 4) illustrates the point; all four biopsy samples from across 
the surgical specimen were assigned CRIS-A classification (100% concordance), 
whereas multiple CMS classifications were assigned from the same four biopsy  
samples; including CMS3 (2/4 biopsies), CMS1 (1/4 biopsies) and CMS4 (1/4 
biopsies). Given the current prognostic algorithm associated with CMS classification, 
these results would be of little utility in patient stratification, as they would reveal a 
patient who has a  tumour with either a good prognosis (CMS1), intermediate 
prognosis (CMS3) or a poor prognosis (CMS4), depending on the region-of-origin of 
the biopsy sample. The 100% concordance observed with CRIS classification, 
independent of region-of-origin, suggests that CRIS classification is the methodology 
of choice when using a single biopsy approach to patient stratification. Ubink et al 
indicate via their analysis that setting a threshold for CMS4 detection across multiple 
biopsies may help ensure a more robust classification [14]. However, taking multiple 
biopsies across the IF and CT regions of tumour in the clinical setting may not 
always be feasible, nor is it part of current standard pathology practice. In contrast to 
the robust and reproducible nature of CMS classification in large resection tissue 
samples, [6] our data reveals multiple conflicting subtype assignments, depending on 
the tumoural region sampled during tissue collection, with stromal-based classifiers 
like CMS specifically when using biopsy samples. We propose that using the CRIS 
classifier transcends this stromal heterogeneity, resulting in a robust patient 
classification methodology regardless of the proportions of TME-derived material 
even in biopsy tissue (Figure 6). 
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Biomarker-informed clinical trials such as FOxTROT (ISRCTN 87163246) and 
FOCUS4 (ISRCTN90061546) have involved application of multiple molecular tests 
on biopsy material which may be limited in quantity (and potentially quality), following 
diagnostic assessment. While these studies have employed mutational status for 
patient stratification, evaluation of transcriptional-based signatures in collaborative 
programmes such as S:CORT aims to provide a clinical rationale for such 
stratification in clinical practice. There is no doubt as to the potential clinical 
importance of the TME and CMS classification system, with numerous studies 
highlighting its prognostic value. However, given the nature of stromal ITH and the 
current lack of a standardised method for collection of biopsy material, even within 
ongoing clinical trials, this method can easily be confounded by sampling bias. The 
implementation of a standardised biopsy collection method may remove this 
confounding issue, but until such a reproducible biopsy protocol is developed, our 
data supports the use of CRIS stratification as the molecular pathology methodology 
of choice underpinning reproducible prospective patient stratification from current 
routine biopsy tissue.  
In addition to a robust subtype assignment and clear prognostic value, the clinical 
relevance of defining CRIS lies in its potential predictive value, which gives insights 
into the biology underlying the epithelial component of the tumour, which may in turn 
guide an informed (targeted) therapy approach. We have previously shown that 
CRIS-C patient-derived xenografts (PDX) respond to EGFR inhibition (cetuximab)[8] 
which was further validated using tumour profiles from a phase II metastatic CRC 
study.[22] Preliminary results from FOxTROT have confirmed the feasibility of 
stratifying colon cancer patients, using pre-treatment biopsies, for targeted 
(panitumumab) and/or cytotoxic chemotherapy treatment in the neo-adjuvant setting. 
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Data presented here support the use of CRIS profiling of pre-treatment biopsy 
material to inform precision oncology stratification based on the specific biology of 
the disease, determined  using diagnostic endoscopic tissue. The “window-of-
opportunity” study design, as used in FOxTROT, urgently requires robust biomarkers 
linked to distinct therapeutic choices in order to select patients for more personalised 
treatments. Based on our findings, classification of samples based on cancer-cell 
intrinsic properties, such as CRIS, are necessary to guide testing of novel treatment 
interventions in the first-line preoperative setting, where they have the greatest 
chance of achieving therapeutic response(s).  
In conclusion, we highlight the robust nature of the CRIS transcriptional classifier in 
diagnostic endoscopic biopsy material, which is the relevant entry point to ongoing 
and forthcoming CRC clinical trials. The limitations of CMS identified previously by 
our group are still evident when using LCM processing of samples, suggesting that 
this time-consuming method does not eliminate the potential for ITH to confound 
patient classification, as previously identified in macrodissected samples. Given the 
limited control over the spatial region-of-origin of biopsy tissue available for analysis, 
our current data support patient stratification using CRIS transcriptional subtypes, 
which minimise potentially confounding ITH. This work provides a strong rationale to 
investigate the prognostic/predictive value of CRIS subtypes in biopsy-led and 
statistically-powered prospective CRC trials.  
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Table 1. The eight rectal cancer biopsy gene expression datasets curated from 
GEO, their sample size and gene expression profiling platform used. 
Data set Sample size Platform 
GSE56699 58 Illumina WG-DASL 
GSE94104 48 Illumina WG-DASL 
GSE3493 46 Affymetrix Human Genome U95 Version 2 Array 
GSE68204 38 Agilent-014850 Whole Genome Microarray 4x44K 
GSE35452 46 Affymetrix Human Genome U133 Plus 2.0 Array 
GSE46862 69 Affymetrix Human Gene 1.0 ST Array 
GSE45404 42 Affymetrix Human Genome U133 Plus 2.0 Array 
GSE87211 196 Agilent-014850 Whole Genome Microarray 4x44K 
Total 543 
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Figure Legends 
Figure 1. Patient stratification using CRC cell intrinsic signatures. (A) left, Using the 
CMS classifier, each sample will be assigned an individual score for CMS1, CMS2, 
CMS3 and CMS4. Boxplots showing relative CMS ratio for CMS1-4 in patient-
matched central tumour (CT) and invasive front (IF) samples (n=20). Right, Dot plot 
comparing normalised random forest posterior probability scores for IF front region of 
stromal and epithelial CMS subtypes (p = 0.0001, students t-test). (B) Dot plot of 
normalised Pearson similarity scores for each gene signature. (C) Table showing 
clustering concordance by gene signature. (D) Caleydo (Stratomex) integrative 
visualisation of CRIS and CMS concordance between matched CT and IF regions.  
Figure 2. Molecular subtyping of rectal cancer biopsies. (A) Bar charts showing the 
proportions, average and total numbers of each CMS and CRIS group across the 
eight rectal cancer biopsy datasets. (B) Caleydo (Stratomex) integrative visualisation 
of CMS and CRIS across the eight rectal cancer biopsy datasets.   
Figure 3. Temporal stability of molecular subtypes in serial biopsies. Caleydo 
(Stratomex) integrative visualisation of CRIS and CMS concordance in serial rectal 
cancer biopsies from AXEBeam Trial (n=10). 
Figure 4. Spatial stability of molecular subtypes in multi-regional biopsies. Pie charts 
showing the concordant classification of multi-regional biopsies from seven surgical 
specimens in the BOSS study into CRIS (left) and CMS (right) subtypes. 
Figure 5. Molecular subtyping and tumour content in biopsy material from phase II 
COPERNICUS clinical trial. (A) Bar charts showing the percentage of patients from 
each subtype left (CMS) and right (CRIS) in COPERNICUS cohort. (B) Dot plots 
showing the comparing tumour percentage between stromal subtypes (CMS1 and 4) 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
and epithelial subtypes (CMS2 and 3) (Student’s t-test, p=0.003). (c) Representative 
H&E images of CMS1 (left), CMS2/3 (middle) and CMS4 (right) biopsies (x10 
magnification).  
Figure 6. Proposed model of stromal heterogeneity confounding CMS subtyping in 
colorectal cancer biopsies. 
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